Why Did Novartis/1A Pharma Withdraw Its Paracetamol Liquid From The German Market?
Executive Summary
HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.
You may also be interested in...
Paracetamol Included In EU List Of Critical Medicines
Paracetamol makes it onto the European Commission's first ever EU-level list of critical medicines whose continuity of supply is a priority and for which “shortages should be avoided.”
AESGP Welcomes EU Pharma Revision But Warns Of ‘Unintended Negative Consequences’
European self-care industry association AESGP says it supports the revision of the EU pharmaceutical legislation “in principle,” but has concerns that some of the proposals “may have unintended negative consequences.”
German Generic Reform To Relax Pediatric Pricing
Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.